Programma workshops BIO-Europe Spring 2011
Array
EBD Group heeft vandaag de workshops bekendgemaakt die op het programma staan voor de samenwerkingsconferentie BIO-Europe Spring 2011, die van 14-16 maart 2011 wordt gehouden in het Milano Convention Center (MIC) in Milaan. De workshops onder leiding van vooraanstaande vakspecialisten verkennen de belangrijkste zakelijke en wetenschappelijke ontwikkelingen die spelen bij het maken van deals.
Er is onder meer een workshop over e Springpigenomica, een fenomeen dat niet alleen vraagtekens plaatst bij lang gekoesterde opvattingen over erfelijkheid, maar ook een revolutionaire routekaart oplevert voor de ontwikkeling van nieuwe farmacogenomische middelen voor diagnostiek en behandeling.
Engelstalig bericht:
EBD Group today announced program workshops that will be featured at the BIO-Europe Spring® 2011 partnering conference to be held March 14–16 at the Milano Convention Center (MIC). Moderated by leading domain experts, the workshops explore the major business and scientific trends shaping the dealmaking landscape.
The BIO-Europe Spring 2011 workshops are:
An Apple a Day… Could It Be True? Epigenomics Shaping Personalized Medicine
Epigenomics is not only challenging long-held notions about heredity but it is also providing a revolutionary roadmap for the development of new pharmacogenomic diagnostics and therapeutics. John Sterling of Genetic Engineering & Biotechnology News (GEN) will lead a panel featuring Mohammad Azab, SuperGen; Paul Denny-Gouldson, IDBS; Nicola Henneberg-Busse, Epigenomics AG; and David Simmons, Cellzome in a discussion of the range of tools and techniques being employed to increase our knowledge of gene expression and pharmacogenomics.
Due Diligence: How To Ensure a Successful Process
M&A or partnering agreement, product or technology—a biotech company should be prepared to open its doors, books and personnel to a potential partner for full disclosure. Moderator Martina Molsbergen of C14 Consulting Group will ask due diligence experts Jonathan Ellis, GlaxoSmithKline; Carl Jessop, AstraZeneca; Lali Reddy, Genentech; Morag Simpson, Shire; and Gregory Wiederrecht, Merck & Co., Inc. to draw on their real world experience to uncover what makes a due diligence best practice.
Oncology Drug Development Partnerships: Will Risk Sharing Models Work?
In this capital-constrained environment, most oncology drug development companies will need clinical-stage partnerships to advance their programs through proof of concept into late stage development. Chris Hollowood of Apposite Capital will lead panelists Lukas Huber, Oncotyrol; Phil L’Huillier, Cancer Research Technology; Elisabeth Lindner, Central European Cooperative Oncology Group (CECOG); and Christian M. Pangratz, NEKTAR in an examination of the new partnering models in oncology, and the pros and cons associated with different strategies.
Understanding the Drivers for Strategic Decision Making
At every stage of its evolution, a development-stage biotech company must operate with a forward-looking perspective. To advance assets, raise funds, select a great management team, and set strategic goals, the company must first evaluate where they want to go, and when and how they plan to get there. Moderator Diane Romza-Kutz of Troutman Sanders will lead panelists Steven P. Damon, Altea Therapeutics; Steve Ellul, Eurand Pharmaceutical Technologies; Leslie Molony, Sanford-Burnham Medical Research Institute; and Michael A. Yeomans, Partners in Pharma in an evaluation of various strategic options emerging biotech companies can choose from.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, the world’s largest stand-alone life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm Americaâ„¢, the fastest growing partnering event in North America
- EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- Biotech Showcaseâ„¢, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world.
Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
